Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic NSCLC (IMpower150)

¹Thoracic Oncology, Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany;²Cancer Institute of Florida, Florida Hospital, Orlando, FL, USA;³Azienda Unità Sanitaria Locale della Romagna, Ravenna, Italy;⁴Instituto Nacional del Tórax (Hospital del Tórax), Santiago, Chile;⁵Moscow City Oncology Hospital, Moscow, Russian Federation;⁶National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan;⁷Medical Oncology, Hospital Universitario Insular de Gran Canaria, Las Palmas, Spain;⁸Centre Hospitalier Universitaire de Grenoble Alpes, Grenoble, France;⁹New England Cancer Specialists, Scarborough, ME, USA;¹⁰Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille, France